Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity

Bone

Volumn 40, Issue 2, 2007, Pages 391-398

  Iida Klein, Akiko ^a,b   Lu, Shi Shou ^a   Cosman, Felicia ^a,b   Lindsay, Robert ^a,b   Dempster, David W ^a,b  

^a HELEN HAYES HOSPITAL   (United States)

^b Clinical Research Center ^*  (United States)

Author keywords

Bone microarchitecture; Cyclic PTH; Mouse; Periosteal bone formation; Trabecular tunneling

Indexed keywords

CALCEIN; PARATHYROID HORMONE[1-34];

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE STRENGTH; BONE STRUCTURE; C57BL 6 MOUSE; CANCELLOUS BONE; CELL ACTIVITY; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; FEMALE; FEMUR; HORMONE ACTION; LUMBAR VERTEBRA; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PARAMETER; PERIOSTEUM; TRABECULAR BONE;

ANIMALS; BONE DENSITY; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PARATHYROID HORMONE; PEPTIDE FRAGMENTS;

EID: 33845995061     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.09.010     Document Type: Article

References (46)

1. Lindsay R., Nieves J., Formica C., Henneman E., Woelfert L., Shen V., et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350 (1997) 550-555
2. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after PTH withdrawal. J. Bone Miner. Res. 16 (2001) 925-931
3. Finkelstein J.S., Hayes A., Hunzelman J.L., and Wyland J.J. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349 (2003) 1216-1226
4. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344 (2001) 1434-1441
5. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282 (1999) 637-645
6. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280 (1998) 2077-2082
7. Iida-Klein A., Zhou H., Lu S.S., Levine L., Ducayen-Knowles M., Dempster D.W., et al. Anabolic action of human parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J. Bone Miner. Res. 17 (2002) 808-816
8. Cosman F., Nieves J.W., Lucky M.M., Zion M., Woelfert L., and Lindsay R. Daily versus cyclic PTH combined with alendronate versus alendronate alone for treatment of osteoporosis. N. Engl. J. Med. 353 (2005) 566-575
9. Iida-Klein A., Hughes C., Shen V., Moreno A., Lu S.S., Dempster D.W., et al. Effects of cyclic vs. daily PTH regimens on bone strength in association with bone density, biochemical markers and bone structure in mice. J. Bone Miner. Res. 21 (2006) 274-283
10. Iida-Klein A., Lu S.S., Kapadia R., Burkhart M., Moreno A., Dempster D.W., et al. Short-term continuous infusion of human PTH1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J. Endocrinol. 186 (2005) 549-557
11. Cefalu C.A. Is bone mineral density predictive of fracture risk reduction?. Curr. Med. Res. Opin. 20 (2004) 341-349
12. Small R.E. Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed 7 (2005) 3-9
13. Ammann P., and Rizzoli R. Bone strength and its determinants. Osteoporosis Int. 14 suppl3 (2003) S13-S18
14. Zhou H., Iida-Klein A., Lu S.S., Levine L., Ducayen-Knowles M., Dempster D.W., et al. The anabolic action of PTH on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone 32 (2003) 513-520
15. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J. Bone Miner. Res. 2 (1987) 595-610
16. Jerome C.P., Burr D.B., Van Bibber T., Hock J.M., and Brommage R. Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). Bone 28 (2001) 150-159
17. Sato M., Westmore M., Ma Y.L., Schmidt A., Zeng Q.Q., Glass E.V., et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J. Bone Miner. Res. 19 (2004) 623-629
18. 3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J. Bone Miner. Res. 11 (1999) 600-613
19. Turner R.T., Evans G.L., Cavolina J.M., Halloran B., and Morey-Holton E. Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hindlimb-unloaded ovariectomized rats. Endocrinology 139 (1998) 4086-4091
20. Kasukawa Y., Miyakoshi N., Itoi E., Tsuchida T., Tamua Y., Kudo T., et al. Effects of h-PTH on cancellous bone mass, connectivity, and bone strength in ovariectomized rats with and without sciatic-neurectomy. J Orthop Res 22 (2004) 457-464
21. Miyakoshi N. Effects of parathyroid hormone on cancellous bone mass and structure in osteoporosis. Curr. Pharmacol. Des. 10 (2004) 2615-2627
22. Schipani E., Ryan H.E., Didrickson S., Kobayashi T., Knight M., and Johnson R.S. Hypoxia in cartilage: HIF-1α is essential for chondrocyte growth arrest and survival. Genes Dev. 15 (2001) 2865-2876
23. Schipani E. Hypoxia and HIF-1a in chondrogenesis. Semin. Cell Dev. Biol. 16 (2005) 539-546
24. Gross T.S., Akeno N., Clemens T.L., Komarova S., Srinivasan S., Weimer D.A., et al. Physiological and genomic consequences of intermittent hypoxia selected contribution: osteocytes upregulate HIF-1 in response to acute disuse and oxygen deprivation. J. Appl. Physiol. 90 (2001) 2514-2519
25. Gross T.S., King K.A., Brabaia N.A., Pathare P., and Srinivasan S. Upregulation of osteopontin by osteocytes deprived of mechanical loading or oxygen. J. Bone Miner. Res. 20 (2005) 250-256
26. Arnett T.R., Gibbons D.C., Utting J.C., Orriss I.R., Hoebertz A., Rosendaal M., et al. Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell. Physiol. 196 (2003) 2-8
27. Fukuoka H., Aoyama M., Miyasawa K., Asai K., and Goto S. Hypoxic stress enhances osteoclast differentiation via increasing IGF2 production by non-osteoclastic cells. Biochem. Biophys. Res.. Commun. 328 (2005) 885-894
28. Ham A.W. Some histophysiological problems peculiar to calcified tissues. J. Bone Joint Surg. 34A (1952) 701-728
29. Aaron J.E., de Vernejoul M.-C., and Kanis J.A. Bone hypertrophy and trabecular generation in Paget's disease and in fluoride-treated osteoporosis. Bone Miner. 17 (1992) 399-413
30. Seeman E. Periosteal bone formation-A neglected determinant of bone strength. N. Engl. J. Med. 349 (2003) 320-323
31. Ahlborg H.G., Johnell O., Turner C.H., Rannevik G., and Karlsson M.K. Bone loss and bone size after menopause. N. Engl. J. Med. 349 (2003) 327-334
32. Samnegard E., Iwaniec U.T., Cullen D.M., Kimmel D.B., and Recker R.R. Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats. Bone 28 (2001) 251-260
33. Kneissel M., Boyde A., and Gasser J.A. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog STZ PTS 893 or human PTH(1-34). Bone 28 (2001) 237-250
34. Mashiba T., Burr D.B., Turner C.H., Sato M., Cain R.L., and Hock J.M. Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 28 (2001) 538-547
35. Zanchetta J.R., Boado C.E., Ferretti J.L., Wang O., Sato W.M.G., Gaich G.A., et al. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J. Bone Miner. Res. 18 (2003) 539-543
36. Uusi-Rasi K., Semanick L.M., Zanchetta J.R., Bogado C.E., Eriksen E.F., Sato M., et al. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36 (2005) 948-958
37. Chen Q., Kaji H., Iu M.-.F., Nomura R., Sowa H., Yamauchi M., et al. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J. Clin. Endocrinol. Metab. 88 (2003) 4655-4658
38. Calvi L.M., Sims N.A., Hunzelman J.L., Knight M.C., Giovannetti A., Saxton J.M., et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J. Clin. Invest. 107 (2001) 277-286
39. Chiusaroli R., Maier A., Knight M.C., Byrne M., Calvi L.M., Baron R., et al. Collagenase cleavage of type I collagen is essential for both basal and parathyroid hormone (PTH)/PTH-related peptide receptor-induced osteoclast activation and has differential effects on discrete bone compartments. Endocrinology 144 (2003) 4106-4116
40. Kitahara K., Ishijima M., Rittling S.R., Tsuji K., Kurosawa H., Nifuji A., et al. Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation. Endocrinology 144 (2003) 2132-2140
41. Bouxsein M.L., Pierroz D.D., Glatt V., Goddard D.S., Cavat F., Rizzoli R., et al. β-arrestin2 regulates the differential response of cortical and trabecular bone to intermittent PTH in female mice. J. Bone Miner. Res. 20 (2005) 635-643
42. Li J., Duncan R.L., Burr D.B., Gattone V.H., and Turner C.H. Parathyroid hormone enhances mechanically induced bone formation, possibly involving L-type voltage-sensitive calcium channels. Endocrinology 144 (2003) 1226-1233
43. Komarova S.V. Mathematical model of paracrine interaction between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone. Endocrinology 146 (2005) 3589-3595
44. Guinness-Hey M., and Hock J.M. Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone 10 (1989) 447-452
45. Qi H., Li M., and Wronski T.J. A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J. Bone Miner. Res. 10 (1995) 948-955
46. Li M., and Wronski T.J. Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 16 (1995) 551-557